Journal
NANO LETTERS
Volume 19, Issue 8, Pages 5185-5193Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.9b01571
Keywords
Adjuvant; cancer cell membrane; cancer immunotherapy; homotypic targeting liposome; photodynamic therapy
Categories
Funding
- National Research Foundation of Korea [2017R1A2B3005842]
- Korea Health Industry Development Institute [HI18C0183]
- Ministry of Health and Welfare, Republic of Korea
- National Research Foundation of Korea [2017R1A2B3005842] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Liposomes are clinically used as drug carriers for cancer therapy; however, unwanted leakage of the encapsulated anticancer drug and poor tumor-targeting efficiency of liposomes may generate toxic side effects on healthy cells and lead to failure of tumor eradication. To overcome these limitations, we functionalized liposomes with a photosensitizer (KillerRed, KR)-embedded cancer cell membrane (CCM). A lipid adjuvant was also embedded in the lipocomplex to promote the anticancer immune response. KR proteins were expressed on CCM and did not leak from the lipocomplex. Owing to the homotypic affinity of the CCM for the source cancer cells, the lipocomplex exhibited a 3.3-fold higher cancer-targeting efficiency in vivo than a control liposome. The liposome functionalized with KR-embedded CCM and lipid adjuvant generated cytotoxic reactive oxygen species in photodynamic therapy and effectively induced anticancer immune responses, inhibiting primary tumor growth and lung metastasis in homotypic tumor-bearing mice. Taken together, the lipocomplex technology may improve liposome-based cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available